Last reviewed · How we verify
NCT03177187: ACE
Combination Study of AZD5069 and Enzalutamide.
Phase 1, PHASE2 trial testing AZD5069 in Metastatic Castration Resistant Prostate Cancer in 30 participants. Terminated before completion.
15 September 2022
Quick facts
| Lead sponsor | Institute of Cancer Research, United Kingdom |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 30 |
| Start date | 13 November 2017 |
| Primary completion | 15 September 2022 |
| Estimated completion | 16 November 2022 |
| Sites | 4 locations across United Kingdom, Switzerland |
Drugs / interventions tested
- AZD5069 — full drug profile →
- Enzalutamide 40 MG — full drug profile →
Conditions studied
- Metastatic Castration Resistant Prostate Cancer — all drugs for Metastatic Castration Resistant Prostate Cancer →
Sponsor
Institute of Cancer Research, United Kingdom
Who can join
18 and older, male only, with Metastatic Castration Resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC). The investigators will be investigating the safety and toxicity of the combination.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K, Shi H, Zhang B, Ou X, et al · · 2021 · cited 687× · PMID 34620838 · DOI 10.1038/s41392-021-00670-9 -
The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.
Cambier S, Gouwy M, Proost P. · · 2023 · cited 387× · PMID 36725964 · DOI 10.1038/s41423-023-00974-6 -
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8 -
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.
Vilgelm AE, Richmond A. · · 2019 · cited 310× · PMID 30873179 · DOI 10.3389/fimmu.2019.00333 -
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.
Fousek K, Horn LA, Palena C. · · 2021 · cited 278× · PMID 32980444 · DOI 10.1016/j.pharmthera.2020.107692 -
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3 -
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P, Ercolano G, Ianaro A. · · 2020 · cited 251× · PMID 32849585 · DOI 10.3389/fimmu.2020.01680 -
Macrophage Polarity and Disease Control.
Kadomoto S, Izumi K, Mizokami A. · · 2021 · cited 245× · PMID 35008577 · DOI 10.3390/ijms23010144
Verify or expand the search:
- PubMed search for NCT03177187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AZD5069
Trials testing the same drug.
- NCT02499328 — Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Car · Phase 1, PHASE2 · completed
Other recruiting trials for Metastatic Castration Resistant Prostate Cancer
Currently open trials in the same condition.
- NCT07093801 — Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer · recruiting
- NCT06830850 — A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With · Phase 1 · recruiting
- NCT06517719 — Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer · recruiting
- NCT05219500 — Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate C · Phase 2 · active not recruiting
- NCT04729114 — A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer · Phase 1 · recruiting
Other Institute of Cancer Research, United Kingdom trials
Trials by the same sponsor.
- NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
- NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
- NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
- NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
- NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03177187 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03177187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing